Belite Bio Announces UKs Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant
November 02, 2025 09:00 ET Â | Source: Belite Bio, Inc MHRA response…
Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy
July 02, 2025 03:00 ET Â | Source: Belite Bio, Inc -Â 500…